Seikagaku Corporation

TSE:4548 Stock Report

Market Cap: JP¥42.8b

Seikagaku Past Earnings Performance

Past criteria checks 5/6

Seikagaku has been growing earnings at an average annual rate of 45.2%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.7% per year. Seikagaku's return on equity is 2.7%, and it has net margins of 5.3%.

Key information

45.2%

Earnings growth rate

45.3%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate5.7%
Return on equity2.7%
Net Margin5.3%
Next Earnings Update07 Feb 2025

Recent past performance updates

Seikagaku's (TSE:4548) Solid Profits Have Weak Fundamentals

Nov 21
Seikagaku's (TSE:4548) Solid Profits Have Weak Fundamentals

Recent updates

Seikagaku's (TSE:4548) Solid Profits Have Weak Fundamentals

Nov 21
Seikagaku's (TSE:4548) Solid Profits Have Weak Fundamentals

Earnings Not Telling The Story For Seikagaku Corporation (TSE:4548)

Aug 06
Earnings Not Telling The Story For Seikagaku Corporation (TSE:4548)

Seikagaku's (TSE:4548) Anemic Earnings Might Be Worse Than You Think

May 21
Seikagaku's (TSE:4548) Anemic Earnings Might Be Worse Than You Think

Seikagaku (TSE:4548) Is Paying Out A Dividend Of ¥13.00

Mar 03
Seikagaku (TSE:4548) Is Paying Out A Dividend Of ¥13.00

Revenue & Expenses Breakdown

How Seikagaku makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4548 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2438,3622,0159,6027,317
30 Jun 2436,5742,2009,2807,303
31 Mar 2436,2132,1868,9607,484
31 Dec 2334,6781,3098,7897,694
30 Sep 2334,2591,1978,4457,954
30 Jun 2334,8102,6308,2358,002
31 Mar 2333,4562,2367,9597,951
31 Dec 2232,8681,9977,8188,505
30 Sep 2231,5791,8557,5098,610
30 Jun 2231,3741,5747,2148,756
31 Mar 2234,8513,7337,0289,005
31 Dec 2134,9947,7477,0857,684
30 Sep 2134,6598,3056,9827,476
30 Jun 2132,4747,3856,9297,530
31 Mar 2127,6624,2626,8097,209
31 Dec 2026,2158216,6177,800
30 Sep 2026,6209036,8347,405
30 Jun 2027,965-11,2907,0577,204
31 Mar 2028,642-10,8397,2926,877
31 Dec 1930,038-9,7907,3296,613
30 Sep 1929,683-10,4347,2746,868
30 Jun 1928,8072,0207,1386,873
31 Mar 1928,3842,2447,1447,148
31 Dec 1828,3601,8257,2528,250
30 Sep 1828,9362,2847,2708,490
30 Jun 1829,8934,2037,3908,413
31 Mar 1830,1753,9227,3378,408
31 Dec 1730,8624,6567,2127,218
30 Sep 1729,9994,3247,1576,930
30 Jun 1728,8222,4237,1047,100
31 Mar 1729,5891,7877,2257,834
31 Dec 1629,6531,0427,2468,781
30 Sep 1630,0931,6507,3109,009
30 Jun 1631,4751,8337,3729,163
31 Mar 1630,9622,5787,2978,649
31 Dec 1530,8843,6257,2128,082
30 Sep 1531,2293,9047,0718,498
30 Jun 1529,7073,4316,9008,309
31 Mar 1529,5223,6506,8628,146
31 Dec 1428,5673,1356,8347,725
30 Sep 1428,4563,3146,8886,917
30 Jun 1429,5443,8596,9796,909
31 Mar 1429,6144,7456,8646,588
31 Dec 1329,1064,9436,6436,488

Quality Earnings: 4548 has high quality earnings.

Growing Profit Margin: 4548's current net profit margins (5.3%) are higher than last year (3.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4548 has become profitable over the past 5 years, growing earnings by 45.2% per year.

Accelerating Growth: 4548's earnings growth over the past year (68.3%) exceeds its 5-year average (45.2% per year).

Earnings vs Industry: 4548 earnings growth over the past year (68.3%) exceeded the Pharmaceuticals industry 12.2%.

Return on Equity

High ROE: 4548's Return on Equity (2.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:43
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Seikagaku Corporation is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Akitada IwasaDaiwa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.
Ippei KogaMarusan Securities Co. Ltd.